RBCC Negotiates Funding Terms With n3D

Emirates PharmaAdvertisement

Rainbow Biosciences, the biotech division of Rainbow Coral Corp. announced today that it’s on the cusp of a major breakthrough in its business relationship with n3D Biosciences.

Last week, management from RBCC and n3D convened to review potential terms for a go-forward relationship. The companies discussed possible funding opportunities that would enable n3D to accelerate its business objectives.

RBCC expects to have a draft agreement finalized as early as next week. The deal would be the culmination of months of work toward an acquisition or joint venture with n3D.

Nano3D is a fully commercialized company that has developed a breakthrough three-dimensional cell culturing system. A funding agreement would allow RBCC to move forward with its global marketing initiative for n3D’s innovative product.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. , Cardinal Health, Inc.  Abbott Laboratories and Affymax, Inc. Follow us on Twitter at www.twitter.com/RBCCinfo.

About Rainbow BioSciences

Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC). The company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit our website at [www.rainbowbiosciences.com]. For investment information and performance data on the company.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone’s past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the company assumes no responsibility to update the information included herein for events occurring after the date hereof.

Emirates PharmaAdvertisement